<?xml version='1.0' encoding='utf-8'?>
<document id="25587127"><sentence text="Mechanism-based inhibitory and peroxisome proliferator-activated receptor α-dependent modulating effects of silybin on principal hepatic drug-metabolizing enzymes."><entity charOffset="108-115" id="DDI-PubMed.25587127.s1.e0" text="silybin" /></sentence><sentence text="Silybin, a major pharmacologically active compound in silymarin, has been widely used in combination with other prescriptions in the clinic to treat hepatitis and a host of other diseases"><entity charOffset="0-7" id="DDI-PubMed.25587127.s2.e0" text="Silybin" /><entity charOffset="54-63" id="DDI-PubMed.25587127.s2.e1" text="silymarin" /><pair ddi="false" e1="DDI-PubMed.25587127.s2.e0" e2="DDI-PubMed.25587127.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25587127.s2.e0" e2="DDI-PubMed.25587127.s2.e1" /></sentence><sentence text=" Previous studies suggested that silybin is a potential inhibitor of multiple drug-metabolizing enzymes (DMEs); however, the in vitro to in vivo translation and the mechanisms involved remain established"><entity charOffset="33-40" id="DDI-PubMed.25587127.s3.e0" text="silybin" /></sentence><sentence text=" The aim of this study was to provide a mechanistic understanding of the regulatory effects of silybin on principal DMEs"><entity charOffset="95-102" id="DDI-PubMed.25587127.s4.e0" text="silybin" /></sentence><sentence text=" Silybin (50 or 150 mg/kg/d) was administered to mice for a consecutive 14 days"><entity charOffset="1-8" id="DDI-PubMed.25587127.s5.e0" text="Silybin" /></sentence><sentence text=" The plasma and hepatic exposure of silybin were detected; the mRNA, protein levels, and enzyme activities of principal DMEs were determined"><entity charOffset="36-43" id="DDI-PubMed.25587127.s6.e0" text="silybin" /></sentence><sentence text=" The results demonstrated that the enzyme activities of CYP1A2, CYP2C, CYP3A11, and UGT1A1 were significantly repressed, whereas little alteration of the mRNA and protein levels was observed" /><sentence text=" Silybin inhibits these DMEs in a mechanism-based and/or substrate-competitive manner"><entity charOffset="1-8" id="DDI-PubMed.25587127.s8.e0" text="Silybin" /></sentence><sentence text=" More importantly, silybin was found to be a weak agonist of peroxisome proliferator-activated receptor (PPAR)α, as evidenced from the molecular docking, reporter gene assay, and the targeting gene expression analysis"><entity charOffset="19-26" id="DDI-PubMed.25587127.s9.e0" text="silybin" /></sentence><sentence text=" However, silybin could significantly compromise the activation of PPARα by fenofibrate, characterized with significantly repressed expression of PPARα targeting genes, including L-FABP, ACOX1, and UGT1A6"><entity charOffset="10-17" id="DDI-PubMed.25587127.s10.e0" text="silybin" /><entity charOffset="76-87" id="DDI-PubMed.25587127.s10.e1" text="fenofibrate" /><entity charOffset="179-185" id="DDI-PubMed.25587127.s10.e2" text="L-FABP" /><pair ddi="false" e1="DDI-PubMed.25587127.s10.e0" e2="DDI-PubMed.25587127.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25587127.s10.e0" e2="DDI-PubMed.25587127.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25587127.s10.e0" e2="DDI-PubMed.25587127.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25587127.s10.e1" e2="DDI-PubMed.25587127.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25587127.s10.e1" e2="DDI-PubMed.25587127.s10.e2" /></sentence><sentence text=" This study suggests that silybin, despite its low bioavailability, may inhibit enzyme activities of multiple DMEs in a mechanism-based mode, and more importantly, may confer significant drug-drug interaction with PPARα agonists via the repression of PPARα activation in a competitive mode"><entity charOffset="26-33" id="DDI-PubMed.25587127.s11.e0" text="silybin" /></sentence><sentence text=" " /></document>